X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers

By Lauren Neves  |    September 19, 2018
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be...   Read More

Saving kids and dogs from shared cancers

By Guest Contributor  |    September 17, 2018
Ulrike Szalay is the Founder and Executive Director of Canines-N-Kids Foundation Did you know? Dogs and children spontaneously develop a number of similar cancers. In fact, cancer is the leading...   Read More

What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?

By Juliet Johnson  |    September 13, 2018
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines.  These...   Read More

New report details the setbacks and challenges to Alzheimer’s research

By Gretta Stone  |    September 12, 2018
Illustrating the challenges of developing medicines to fight Alzheimer’s disease, a new analysis found that between 1998 and 2017, there were 146 unsuccessful medicines in clinical trials for...   Read More

Disrupting Alzheimer's

By Andrew Powaleny  |    September 10, 2018
We are living in a new era of medicine, where treatments and even cures once believed to be impossible are today a reality. But this immense progress does not apply universally and there have been...   Read More

Guest post: Developing new payment models to ensure patients have access to high-investment therapies

By Guest Contributor  |    September 6, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New study finds some hospitals mark up medicine prices at least 700 percent

By Holly Campbell  |    September 5, 2018
A new analysis from The Moran Company found nearly one in five hospitals marks up medicine prices 700 percent or more. With this 700 percent markup, a $150 medicine purchased by a hospital could...   Read More

A call to action on Overdose Awareness Day

By Guest Contributor  |    August 31, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment

By Guest Contributor  |    August 29, 2018
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Lauren Gilstrap, MD, MPH. ...   Read More

Number of value-based contracts continues to rise

By Michelle Drozd  |    August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates